Abstract: Provided herein are, inter alia, methods for treating cancers having KRAS mutations using ITGB4/PXN pathway inhibitors, Wnt/?-catenin pathway inhibitors, KRAS pathway inhibitors, and combinations thereof; and pharmaceutical compositions comprising the ITGB4/PXN pathway inhibitors, Wnt/?-catenin pathway inhibitors, KRAS pathway inhibitors, and combinations thereof.

Abstract: Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

Abstract: The present invention provides a method of treating a subject suffering from SCLC comprising administering to the subject an effective amount of a PP2A inhibitor and optionally one or more anti-cancer agents.

Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. The invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-CBL.

Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.

Abstract: Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

Abstract: Disclosed herein are methods and compositions for alleviating resistance to chemotherapy in a subject using one or more therapeutic agents that perturb the interaction between integrin ?4 (ITGB4) and paxillin (PXN), e.g., by inhibiting the expression of ITGB4, PXN, or both. Also disclosed is a combinational therapy for treating cancer with a chemotherapeutic agent such as cisplatin or carboplatin and an inhibitor of ITGB4, PXN or both, such as carfilzomib.

Abstract: Disclosed herein, inter alia, are pyridopyrazines and methods of using the same.

Abstract: Disclosed herein, inter alia, are pyridopyrazines and methods of using the same.

Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.

Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. The invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-CBL.

Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. The invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-CBL.

Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. The invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-CBL.

Abstract: Disclosed herein are methods for assessing risk of metastasis of a tumor in a mammal by determining the paxillin gene copy number per cell in the tumor or by detecting the presence of a paxillin mutation in the tumor. The presence of an increased paxillin gene copy number or a paxillin mutation is indicative of an increased risk of metastasis. Methods of staging tumors and methods of reducing invasiveness or metastasis of a cancer cell are also provided. Oligonucleotides comprising a paxillin mutation and antibodies capable of recognizing a paxillin mutant are disclosed.

Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-Met.

Abstract: The invention provides a method of treating abnormal cell growth in a mammal, such as a human, by administering to the mammal a therapeutically effective amount of a c-MET inhibitor and a mammalian target of rapamycin (mTOR) inhibitor.

Abstract: The invention provides novel methods and compositions for modulating small cell lung cancer (SCLC) proliferation and metastasis through modulation of CXCR4 activity or expression. Also provided are methods for identifying compounds that modulate SCLC proliferation and metastasis through modulation of CXCR4 activity or expression. Further provided are methods for treating SCLC proliferation and metastasis, as well as methods for determining whether subjects are suitable candidates for treatment of SCLC via modulation of CXCR4 activity.